Skip to main content

Advertisement

SpringerLink
Log in

Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology

  • Original Article
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

The Indian Society of Gastroenterology (ISG) felt the need to organize a consensus on Helicobacter pylori (H. pylori) infection and to update the current management of H. pylori infection; hence, ISG constituted the ISG’s Task Force on Helicobacter pylori. The Task Force on H. pylori undertook an exercise to produce consensus statements on H. pylori infection. Twenty-five experts from different parts of India, including gastroenterologists, pathologists, surgeons, epidemiologists, pediatricians, and microbiologists participated in the meeting. The participants were allocated to one of following sections for the meeting: Epidemiology of H. pylori infection in India and H. pylori associated conditions; diagnosis; treatment and retreatment; H. pylori and gastric cancer, and H. pylori prevention/public health. Each group reviewed all published literature on H. pylori infection with special reference to the Indian scenario and prepared appropriate statements on different aspects for voting and consensus development. This consensus, which was produced through a modified Delphi process including two rounds of face-to-face meetings, reflects our current understanding and recommendations for the diagnosis and management of H. pylori infection. These consensus should serve as a reference for not only guiding treatment of H. pylori infection but also to guide future research on the subject.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Proceedings of the 1st National Workshop on Helicobacter pylori: the Indian scenario. Mumbai, India, February 22-23, 1997. Indian J Gastroenterol. 1997;16 Suppl 1:S1–35.

  2. Proceedings of the 2nd National Workshop on Helicobacter pylori: management recommendations in India. Thrissur, Kerala, February 20, 1999. Indian J Gastroenterol. 2000;19 Suppl 1:S1–40.

  3. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–600.

    Article  PubMed  Google Scholar 

  4. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1–20.

    Article  CAS  PubMed  Google Scholar 

  5. Kim SG, Jung H-K, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371–86.

    Article  PubMed  Google Scholar 

  6. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–81.

    Article  CAS  PubMed  Google Scholar 

  7. Chey WD, Wong BCY. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–25.

    Article  CAS  PubMed  Google Scholar 

  8. The periodic health examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1984;130:1278–85.

  9. Bhatia SJ, Reddy DN, Ghoshal UC, et al. Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2011;30:118–27.

    Article  PubMed  Google Scholar 

  10. Morris AJ. Long-term follow-up of voluntary ingestion of Helicobacter pylori. Ann Intern Med. 1991;114:662–3.

    Article  CAS  PubMed  Google Scholar 

  11. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med J Aust. 1985;142:436–9.

    Article  CAS  PubMed  Google Scholar 

  12. Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter. 2017;22 Suppl 1. https://doi.org/10.1111/hel.12403

  13. Ahmed KS, Khan AA, Ahmed I, et al. Prevalence study to elucidate the transmission pathways of Helicobacter pylori at oral and gastroduodenal sites of a South Indian population. Singap Med J. 2006;47:291–6.

    CAS  Google Scholar 

  14. Singh V, Trikha B, Vaiphei K, Nain CK, Thennarasu K, Singh K. Helicobacter pylori: evidence for spouse-to-spouse transmission. J Gastroenterol Hepatol. 1999;14:519–22.

  15. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Saxena A, Shukla S, Prasad KN, Ghoshal UC. Virulence attributes of Helicobacter pylori isolates & their association with gastroduodenal disease. Indian J Med Res. 2011;133:514–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Adlekha S, Chadha T, Krishnan P, Sumangala B. Prevalence of helicobacter pylori infection among patients undergoing upper gastrointestinal endoscopy in a medical college hospital in kerala. India Ann Med Health Sci Res. 2013;3:559–63.

    Article  CAS  PubMed  Google Scholar 

  18. Shukla SK, Prasad KN, Tripathi A, et al. Helicobacter pylori cagL amino acid polymorphisms and its association with gastroduodenal diseases. Gastric Cancer. 2013;16:435–9.

    Article  CAS  PubMed  Google Scholar 

  19. Sharma PK, Suri TM, Venigalla PM, et al. Atrophic gastritis with high prevalence of Helicobacter pylori is a predominant feature in patients with dyspepsia in a high altitude area. Trop Gastroenterol. 2014;35:246–51.

    Article  PubMed  Google Scholar 

  20. Kolekar RV, Gadgil A, Bhade SPD, et al. Study on urea breath test a tool for Helicobacter pylori infection. Radiat Prot Environ. 2016;39:146–8.

    Article  Google Scholar 

  21. Saha R, Roy P, Das S, Kaur N, Kumari A, Kaur IR. Application of a stool antigen test to evaluate the burden of Helicobacter pylori infection in dyspepsia patients. Indian J Pathol Microbiol. 2016;59:66–8.

  22. Satpathi P, Satpathi S, Mohanty S, Mishra SK, Behera PK, Maity AB. Helicobacter pylori infection in dyspeptic patients in an industrial belt of India. Trop Doct. 2017;47:2–6.

  23. Dutta AK, Reddy VD, Iyer VH, Unnikrishnan LS, Chacko A. Exploring current status of Helicobacter pylori infection in different age groups of patients with dyspepsia. Indian J Gastroenterol. 2017;36:509–13.

  24. Mukhopadhyay DK, Tandon RK, Dasarathy S, Mathur M, Wali JP. A study of Helicobacter pylori in north Indian subjects with non-ulcer dyspepsia. Indian J Gastroenterol. 1992;11:76–9.

  25. Gill HH, Desai HG, Majmudar P, Mehta PR, Prabhu SR. Epidemiology of Helicobacter pylori: the Indian scenario. Indian J Gastroenterol. 1993;12:9–11.

  26. Prasad S, Mathan M, Chandy G, et al. Prevalence of Helicobacter pylori in southern Indian controls and patients with gastroduodenal disease. J Gastroenterol Hepatol. 1994;9:501–6.

    Article  CAS  PubMed  Google Scholar 

  27. Romshoo GJ, Malik GM, Bhat MY, Rather AR, Basu JA, Qureshi KA. Helicobacter pylori associated antral gastritis in peptic ulcer disease patients and normal healthy population of kashmir. India. Diagn Ther Endosc. 1998;4:135–9.

  28. Jain A, Buddhiraja S, Khurana B, et al. Risk factors for duodenal ulcer in north India. Trop Gastroenterol. 1999;20:36–9.

    CAS  PubMed  Google Scholar 

  29. Tovey FI, Hobsley M, Kaushik SP, et al. Duodenal gastric metaplasia and Helicobacter pylori infection in high and low duodenal ulcer-prevalent areas in India. J Gastroenterol Hepatol. 2004;19:497–505.

    Article  PubMed  Google Scholar 

  30. Singh V, Trikha B, Nain CK, Singh K, Vaiphei K. Epidemiology of Helicobacter pylori and peptic ulcer in India. J Gastroenterol Hepatol. 2002;17:659–65.

  31. Mhaskar RS, Ricardo I, Azliyati A, et al. Assessment of risk factors of helicobacter pylori infection and peptic ulcer disease. J Global Infect Dis. 2013;5:60–7.

    Article  Google Scholar 

  32. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ. 1999;319:1040–4.

    CAS  PubMed  Google Scholar 

  33. Moayyedi P, Forman D, Braunholtz D, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 2000;95:1448–55.

    Article  CAS  PubMed  Google Scholar 

  34. Kashyap B, Kaur IR, Garg PK, Das D, Goel S. 'Test and treat' policy in dyspepsia: time for a reappraisal. Trop Doct. 2012;42:109–11.

  35. Hobsley M, Tovey FI, Holton J. Precise role of H pylori in duodenal ulceration. World J Gastroenterol. 2006;12:6413–9.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.

    Article  CAS  PubMed  Google Scholar 

  37. Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Eradication of Helicobacter pylori and gastric cancer: a systematic review and meta-analysis of cohort studies. J Natl Cancer Inst. 2016;108:djw132.

    Article  PubMed  Google Scholar 

  38. Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2015:CD005583.

  39. Khanna AK, Seth P, Nath G, Dixit VK, Kumar M. Correlation of Helicobacter pylori and gastric carcinoma. J Postgrad Med. 2002;48:27–8.

  40. Phukan RK, Narain K, Zomawia E, Hazarika NC, Mahanta J. Dietary habits and stomach cancer in Mizoram. India. J Gastroenterol. 2006;41:418–24.

  41. Misra V, Pandey R, Misra SP, Dwivedi M. Helicobacter pylori and gastric cancer: Indian enigma. World J Gastroenterol. 2014;20:1503–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ruiz B, Correa P, Fontham ETH, Ramakrishnan T. Antral atrophy, Helicobacter pylori colonization, and gastric pH. Am J Clin Pathol. 1996;105:96–101.

    Article  CAS  PubMed  Google Scholar 

  43. Stolte M, Bayerdörffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut. 2002;50 Suppl 3 :III19–24.

    PubMed  PubMed Central  Google Scholar 

  44. Dhali GK, Garg PK, Sharma MP. Role of anti-Helicobacter pylori treatment in H. pylori-positive and cytoprotective drugs in H. pylori-negative, non-ulcer dyspepsia: results of a randomized, double-blind, controlled trial in Asian Indians. J Gastroenterol Hepatol. 1999;14:523–8.

    Article  CAS  Google Scholar 

  45. Sodhi JS, Javid G, Zargar SA, et al. Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir. India J Gastroenterol Hepatol. 2013;28:808–13.

    Article  CAS  PubMed  Google Scholar 

  46. Du LJ, Chen BR, Kim JJ, Kim S, Shen JH, Dai N. Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis. World J Gastroenterol. 2016;22:3486–95.

  47. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99:1833–55.

    Article  PubMed  Google Scholar 

  48. Kate V, Ananthakrishnan N, Tovey FI. Is Helicobacter pylori infection the primary cause of duodenal ulceration or a secondary factor? A review of the evidence. Gastroenterol Res Pract. 2013;2013:425840.

  49. Bose AC, Kate V, Ananthakrishnan N, Parija SC. Helicobacter pylori eradication prevents recurrence after simple closure of perforated duodenal ulcer. J Gastroenterol Hepatol. 2007;22:345–8.

    Article  PubMed  Google Scholar 

  50. Kang JY. Geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:705–17.

    Article  CAS  PubMed  Google Scholar 

  51. Raghunath A, Hungin APS, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ. 2003;326:737.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Lee A, Dixon MF, Danon SJ, et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol. 1995;7:461–5.

    CAS  PubMed  Google Scholar 

  53. Choudhuri G, Mohindra S. Epidemiology of Helicobacter pylori in India. Indian J Gastroenterol. 2000;19 Suppl 1:S3–5.

  54. Nam SY, Choi IJ, Ryu KH, Kim BC, Kim CG, Nam BH. Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. Am J Gastroenterol. 2010;105:2153–62.

  55. Chung SJ, Lim SH, Choi J, et al. Helicobacter pylori serology inversely correlated with the risk and severity of reflux esophagitis in Helicobacter pylori endemic area: a matched case-control study of 5,616 health check-up Koreans. J Neurogastroenterol Motil. 2011;17:267–73.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Gunji T, Sato H, Iijima K, et al. Risk factors for erosive esophagitis: a cross-sectional study of a large number of Japanese males. J Gastroenterol. 2011;46:448–55.

    Article  PubMed  Google Scholar 

  57. Chiba H, Gunji T, Sato H, et al. A cross-sectional study on the risk factors for erosive esophagitis in young adults. Intern Med. 2012;51:1293–9.

    Article  PubMed  Google Scholar 

  58. Ashktorab H, Entezari O, Nouraie M, et al. Helicobacter pylori protection against reflux esophagitis. Dig Dis Sci. 2012;57:2924–8.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Sonnenberg A, Lash RH, Genta RM. A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology. 2010;139:1894–901.

    Article  PubMed  Google Scholar 

  60. Thrift AP, Pandeya N, Smith KJ, et al. Helicobacter pylori infection and the risks of Barrett’s oesophagus: a population-based case-control study. Int J Cancer. 2012;130:2407–16.

    Article  CAS  PubMed  Google Scholar 

  61. Goh K-L. Gastroesophageal reflux disease in Asia: a historical perspective and present challenges. J Gastroenterol Hepatol. 2011;26 Suppl 1:2–10.

    Article  PubMed  Google Scholar 

  62. Ghoshal UC, Chourasia D. Gastroesophageal reflux disease and Helicobacter pylori: what may be the relationship? J Neurogastroenterol Motil. 2010;16:243–50.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Lee HL, Eun CS, Lee OY, et al. Association between erosive esophagitis and visceral fat accumulation quantified by abdominal CT scan. J Clin Gastroenterol. 2009;43:240–3.

    Article  PubMed  Google Scholar 

  64. Chung SJ, Kim D, Park MJ, et al. Metabolic syndrome and visceral obesity as risk factors for reflux oesophagitis: a cross-sectional case-control study of 7078 Koreans undergoing health check-ups. Gut. 2008;57:1360–5.

    Article  CAS  PubMed  Google Scholar 

  65. Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. Aliment Pharmacol Ther. 2011;33:922–9.

    Article  CAS  PubMed  Google Scholar 

  66. Wu JC, Chan FK, Wong SK, Lee YT, Leung WK, Sung JJ. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment Pharmacol Ther. 2002;16:545–52.

  67. Chen T-S, Chang F-Y. The prevalence and risk factors of reflux esophagitis among adult Chinese population in Taiwan. J Clin Gastroenterol. 2007;41:819–22.

    Article  PubMed  Google Scholar 

  68. Yarandi S-S, Nasseri-Moghaddam S, Mostajabi P, Malekzadeh R. Overlapping gastroesophageal reflux disease and irritable bowel syndrome: increased dysfunctional symptoms. World J Gastroenterol. 2010;16:1232–8.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett’s oesophagus. Gut. 1997;40:9–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Gisbert JP, de Pedro A, Losa C, Barreiro A, Pajares JM. Helicobacter pylori and gastroesophageal reflux disease: lack of influence of infection on twentyfour-hour esophageal pH monitoring and endoscopic findings. J Clin Gastroenterol. 2001;32:210–4.

  71. Nordenstedt H, Nilsson M, Johnsen R, Lagergren J, Hveem K. Helicobacter pylori infection and gastroesophageal reflux in a population-based study (The HUNT Study). Helicobacter. 2007;12:16–22.

    Article  PubMed  Google Scholar 

  72. Anderson LA, Murphy SJ, Johnston BT, et al. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut. 2008;57:734–9.

    Article  CAS  PubMed  Google Scholar 

  73. Corley DA, Kubo A, Levin TR, et al. Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study. Gut. 2008;57:727–33.

    Article  CAS  PubMed  Google Scholar 

  74. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut. 2001;49:330–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol. 1999;34:553–9.

  76. Rajendra S, Ackroyd R, Robertson IK, Ho JJ, Karim N, Kutty KM. Helicobacter pylori, ethnicity, and the gastroesophageal reflux disease spectrum: a study from the East. Helicobacter. 2007;12:177–83.

  77. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol. 2002;97:2992–7.

    Article  PubMed  Google Scholar 

  78. Harvey RF, Lane JA, Murray LJ, et al. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. BMJ. 2004;328:1417.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Raghunath AS, Hungin APS, Wooff D, Childs S. The effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther. 2004;20:733–44.

    Article  CAS  PubMed  Google Scholar 

  80. Pilotto A, Perri F, Leandro G, Franceschi M. Aging and Acid-Related Disease Study Group. Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study. Gerontology. 2006;52:99–106.

    Article  PubMed  Google Scholar 

  81. Schwizer W, Menne D, Schütze K, et al. The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: a parallel-group, double-blind, placebo-controlled multicentre study. United European Gastroenterol J. 2013;1:226–35.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Xue Y, Zhou L-Y, Lin S-R, et al. Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study. Chin Med J. 2015;128:995–9.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Kim N, Lee SW, Kim JI, et al. Effect of Helicobacter pylori eradication on the development of reflux esophagitis and gastroesophageal reflux symptoms: a nationwide multi-center prospective study. Gut Liver. 2011;5:437–46.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013;25:1195–205.

    CAS  PubMed  Google Scholar 

  85. Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol. 2010;105:1007–13.

    Article  PubMed  Google Scholar 

  86. Qian B, Ma S, Shang L, Qian J, Zhang G. Effects of Helicobacter pylori eradication on gastroesophageal reflux disease. Helicobacter. 2011;16:255–65.

    Article  PubMed  Google Scholar 

  87. Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2012;47:129–35.

    Article  PubMed  Google Scholar 

  88. Sharma P, Wani S, Romero Y, Johnson D, Hamilton F. Racial and geographic issues in gastroesophageal reflux disease. Am J Gastroenterol. 2008;103:2669–80.

  89. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet. 2001;357:1738–42.

    Article  CAS  PubMed  Google Scholar 

  90. Raghunath AS, O’Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22 Suppl 1:55–63.

    Article  CAS  PubMed  Google Scholar 

  91. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4–19.

    Article  CAS  PubMed  Google Scholar 

  92. Delaney B, McColl K. Review article: Helicobacter pylori and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22 Suppl 1:32–40.

    Article  PubMed  Google Scholar 

  93. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661–9.

    Article  CAS  PubMed  Google Scholar 

  94. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter. 2000;5:206–14.

    Article  CAS  PubMed  Google Scholar 

  95. Katelaris PH. Gastro-oesophageal reflux disease and Helicobacter pylori. Minerva Gastroenterol Dietol. 2003;49:235–41.

    CAS  PubMed  Google Scholar 

  96. Mason JM, Raghunath AS, Hungin APS, Jackson W. Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. Aliment Pharmacol Ther. 2008;28:1297–303.

  97. Hong SJ, Kim SW. Helicobacter pylori infection in gastroesophageal reflux disease in the Asian countries. Gastroenterol Res Pract. 2015;2015:985249.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Graham DY. Helicobacter pylori is not and never was “protective” against anything, including GERD. Dig Dis Sci. 2003;48:629–30.

    Article  PubMed  Google Scholar 

  99. Gatenby P, Soon Y. Barrett’s oesophagus: evidence from the current meta-analyses. World J Gastrointest Pathophysiol. 2014;5:178–87.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Graham DY, Yamaoka Y, Malaty HM. Contemplating the future without Helicobacter pylori and the dire consequences hypothesis. Helicobacter. 2007;12:64–8.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Gudlaugsdottir S, van Dekken H, Stijnen T, Wilson JHP. Prolonged use of proton pump inhibitors, CagA status, and the outcome of Helicobacter pylori gastritis. J Clin Gastroenterol. 2002;34:536–40.

    Article  CAS  PubMed  Google Scholar 

  102. Holcombe C. Helicobacter pylori: the African enigma. Gut. 1992;33:429–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21:1411–8.

    Article  CAS  PubMed  Google Scholar 

  104. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–8.

    Article  CAS  PubMed  Google Scholar 

  105. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967–73.

    Article  CAS  PubMed  Google Scholar 

  106. Goni E, Franceschi F. Helicobacter pylori and extragastric diseases. Helicobacter. 2016;21 Suppl 1:45–8.

    Article  PubMed  Google Scholar 

  107. Qu X-H, Huang X-L, Xiong P, et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol. 2010;16:886–96.

    CAS  PubMed  Google Scholar 

  108. Valiyaveettil AN, Hamide A, Bobby Z, Krishnan R. Effect of anti-Helicobacter pylori therapy on outcome of iron-deficiency anemia: a randomized, controlled study. Indian J Gastroenterol. 2005;24:155–7.

    PubMed  Google Scholar 

  109. Malik R, Guleria K, Kaur I, Sikka M, Radhakrishnan G. Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study. Indian J Med Res. 2011;134:224–31.

  110. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113:1231–40.

    Article  CAS  PubMed  Google Scholar 

  111. Noonavath RN, Lakshmi CP, Dutta TK, Kate V. Helicobacter pylori eradication in patients with chronic immune thrombocytopenic purpura. World J Gastroenterol. 2014;20:6918–23.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Kalkan Ç, Karakaya F, Tüzün A, Gençtürk ZB, Soykan I. Factors related to low serum vitamin B12 levels in elderly patients with non-atrophic gastritis in contrast to patients with normal vitamin B12 levels. Geriatr Gerontol Int. 2016;16:686–92.

  113. Kountouras J, Polyzos SA, Grigoriadis N, Deretzi G. Helicobacter pylori-related vitamin B12 deficiency: a potential contributor in neuropsychiatric disorders. Indian J Psychol Med. 2015;37:475–6.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Rasool S, Abid S, Iqbal MP, Mehboobali N, Haider G, Jafri W. Relationship between vitamin B12, folate and homocysteine levels and H. pylori infection in patients with functional dyspepsia: a cross-section study. BMC Res Notes. 2012;5:206.

  115. Bansal D, Patwari AK, Malhotra VL, Malhotra V, Anand VK. Helicobacter pylori infection in recurrent abdominal pain. Indian Pediatr. 1998;35:329–35.

  116. Yoshida NR, Webber EM, Fraser RB, Ste-Marie MT, Giacomantonio JM. Helicobacter pylori is not associated with nonspecific abdominal pain in children. J Pediatr Surg. 1996;31:747–9.

  117. O'Donohoe JM, Sullivan PB, Scott R, Rogers T, Brueton MJ, Barltrop D. Recurrent abdominal pain and Helicobacter pylori in a community-based sample of London children. Acta Paediatr. 1996;85:961–4.

  118. Bode G, Rothenbacher D, Brenner H, Adler G. Helicobacter pylori and abdominal symptoms: a population-based study among preschool children in southern Germany. Pediatrics. 1998;101:634–7.

    Article  CAS  PubMed  Google Scholar 

  119. Tindberg Y, Nyrén O, Blennow M, Granström M. Helicobacter pylori infection and abdominal symptoms among Swedish school children. J Pediatr Gastroenterol Nutr. 2005;41:33–8.

    Article  PubMed  Google Scholar 

  120. Spee LA, Madderom MB, Pijpers M, van Leeuwen Y, Berger MY. Association between helicobacter pylori and gastrointestinal symptoms in children. Pediatrics. 2010;125:e651–69.

  121. Ashorn M, Rägö T, Kokkonen J, Ruuska T, Rautelin H, Karikoski R. Symptomatic response to Helicobacter pylori eradication in children with recurrent abdominal pain: double blind randomized placebo-controlled trial. J Clin Gastroenterol. 2004;38:646–50.

  122. Singh M, Prasad KN, Yachha SK, Saxena A, Krishnani N. Helicobacter pylori infection in children: prevalence, diagnosis and treatment outcome. Trans R Soc Trop Med Hyg. 2006;100:227–33.

  123. Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53:230–43.

    Article  PubMed  Google Scholar 

  124. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017;64:991–1003.

    Article  PubMed  Google Scholar 

  125. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.

    Article  CAS  PubMed  Google Scholar 

  126. Nocon M, Kuhlmann A, Leodolter A, et al. Efficacy and cost-effectiveness of the 13C-urea breath test as the primary diagnostic investigation for the detection of Helicobacter pylori infection compared to invasive and non-invasive diagnostic tests. GMS Health Technol Assess. 2009;5:Doc14.

    PubMed  PubMed Central  Google Scholar 

  127. Kato S, Nakayama K, Minoura T, et al. Comparison between the 13C-urea breath test and stool antigen test for the diagnosis of childhood Helicobacter pylori infection. J Gastroenterol. 2004;39:1045–50.

    Article  PubMed  Google Scholar 

  128. El-Shabrawi M, El-Aziz NA, El-Adly TZ, et al. Stool antigen detection versus 13C-urea breath test for non-invasive diagnosis of pediatric Helicobacter pylori infection in a limited resource setting. Arch Med Sci. 2018;14:69–73.

    Article  CAS  PubMed  Google Scholar 

  129. Pandya HB, Patel JS, Agravat HH. Singh N kumar R. Non-invasive diagnosis of Helicobacter pylori: evaluation of two enzyme immunoassays, testing serum IgG and IgA response in the Anand District of Central Gujarat, India. J Clin Diagn Res. 2014;8:DC12–5.

    PubMed  PubMed Central  Google Scholar 

  130. Talebi Bezmin Abadi A. Diagnosis of Helicobacter pylori using invasive and noninvasive approaches. J Pathog. 2018;2018:9064952.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  131. Gatta L, Vakil N, Ricci C, et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol. 2004;99:823–9.

    Article  CAS  PubMed  Google Scholar 

  132. Connor SJ, Ngu MC, Katelaris PH. The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with Helicobacter pylori. Eur J Gastroenterol Hepatol. 1999;11:1135–8.

    Article  CAS  PubMed  Google Scholar 

  133. Moon SW, Moon SW, Kim TH, et al. united rapid urease test is superior than separate test in detecting Helicobacter pylori at the gastric antrum and body specimens. Clin Endosc. 2012;45:392–6.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Seth A, Kakkar S, Manchanda G. Role of Biopsy from gastric corpus in diagnosis of Helicobacter pylori infection in patients on acid suppression therapy. Med J Armed Forces India. 2003;59:216–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–81.

    Article  CAS  PubMed  Google Scholar 

  136. Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol. 1998;93:569–73.

    Article  CAS  PubMed  Google Scholar 

  137. Kuo Y-T, Liou J-M, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707–15.

    Article  PubMed  Google Scholar 

  138. Wani FA, Bashir G, Khan MA, Zargar SA, Rasool Z, Qadri Q. Antibiotic resistance in Helicobacter pylori: A mutational analysis from a tertiary care hospital in Kashmir, India. Indian J Med Microbiol. 2018;36:265–72.

  139. Pandya HB, Agravat HH, Patel JS, Sodagar NRK. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian J Med Microbiol. 2014;32:408–13.

    Article  CAS  PubMed  Google Scholar 

  140. Chen Y-L, Mo X-Q, Huang G-R, et al. Gene polymorphisms of pathogenic Helicobacter pylori in patients with different types of gastrointestinal diseases. World J Gastroenterol. 2016;22:9718–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514–33.

    Article  CAS  PubMed  Google Scholar 

  142. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42.

    Article  CAS  PubMed  Google Scholar 

  143. Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol. 2003;18:1373–8.

    Article  CAS  PubMed  Google Scholar 

  144. Bhatia V, Ahuja V, Das B, Bal C, Sharma MP. Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. J Gastroenterol Hepatol. 2004;19:619–25.

  145. Datta S, Chattopadhyay S, Patra R, et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther. 2005;22:51–7.

    Article  CAS  PubMed  Google Scholar 

  146. Vagarali MA, Metgud SC, Bannur H, Karadesai SG, Nagmoti JM. Clinical significance of various diagnostic techniques and emerging antimicrobial resistance pattern of Helicobacter pylori from gastric biopsy samples. Indian J Med Microbiol. 2015;33:560–4.

  147. Gehlot V, Mahant S, Mukhopadhyay AK, et al. Antimicrobial susceptibility profiles of Helicobacter pylori isolated from patients in North India. J Glob Antimicrob Resist. 2016;5:51–6.

    Article  PubMed  Google Scholar 

  148. Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol. 2003;15:27–33.

    Article  CAS  PubMed  Google Scholar 

  149. Prasertpetmanee S, Mahachai V, Vilaichone R. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter. 2013;18:270–3.

    Article  CAS  PubMed  Google Scholar 

  150. Gu Q, Xia HHX, Wang JD, et al. Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy. Digestion. 2006;73:101–6.

    Article  CAS  PubMed  Google Scholar 

  151. Tong Y-F, Lv J, Ying L-Y, et al. Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance. World J Gastroenterol. 2015;21:13073–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Misra R, Bhagat M, Ahmed N. Helicobacter pylori in dyspepsia – antibiotic sensitivity and virulence patterns. Med J Armed Forces India. 2006;62:22–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206–14.

    Article  CAS  PubMed  Google Scholar 

  154. Kim SE, Park MI, Park SJ, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30:801–7.

    Article  PubMed  Google Scholar 

  155. Bhasin DK, Sharma BC, Ray P, Pathak CM, Singh K. Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India. Helicobacter. 2000;5:84–7.

  156. Chaudhary A, Ahuja V, Bal CS, Das B, Pandey RM, Sharma MP. Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study. Helicobacter. 2004;9:124–9.

  157. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:603–9.

  158. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013:CD008337.

  159. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther. 2015;41:581–9.

    Article  CAS  PubMed  Google Scholar 

  160. Ashokkumar S, Agrawal S, Mandal J, Sureshkumar S, Sreenath GS, Kate V. Hybrid Therapy versus Sequential Therapy for Eradication of Helicobacter pylori: A Randomized Controlled Trial. J Pharmacol Pharmacother. 2017;8:62–7.

  161. Hsu P-I, Lin P-C, Graham DY. Hybrid therapy for Helicobacter pylori infection: a systemic review and meta-analysis. World J Gastroenterol. 2015;21:12954–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther. 2004;20:1071–82.

    Article  CAS  PubMed  Google Scholar 

  163. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843–61.

    Article  CAS  PubMed  Google Scholar 

  164. Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41:768–75.

    Article  CAS  PubMed  Google Scholar 

  165. Jheng G-H, Wu I-C, Shih H-Y, et al. Comparison of second-line quadruple therapies with or without bismuth for Helicobacter pylori infection. Biomed Res Int. 2015;2015:163960.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  166. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther. 2005;22:45–9.

    Article  CAS  PubMed  Google Scholar 

  167. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24:1469–74.

  168. Gisbert JP, Castro-Fernández M, Bermejo F, et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol. 2006;101:243–7.

  169. Marin AC, Nyssen OP, McNicholl AG, Gisbert JP. Efficacy and safety of quinolone-containing rescue therapies after the failure of non-bismuth quadruple treatments for Helicobacter pylori eradication: systematic review and meta-analysis. Drugs. 2017;77:765–76.

    Article  CAS  PubMed  Google Scholar 

  170. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med. 2015;54:703–10.

    Article  PubMed  Google Scholar 

  171. Kim JS, Park SM, Kim B-W. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30:1338–45.

    Article  CAS  PubMed  Google Scholar 

  172. Li B-Z, Threapleton DE, Wang J-Y, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  173. Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network metaanalysis. Helicobacter. 2017;22. https://doi.org/10.1111/hel.12389.

  174. Song Z-Q, Zhou L-Y. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol. 2016;22:4766–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Das R, Sureshkumar S, Sreenath GS, Kate V. Sequential versus concomitant therapy for eradication of helicobacter pylori in patients with perforated duodenal ulcer: a randomized trial. Saudi J Gastroenterol. 2016;22:309–15.

    Article  PubMed  PubMed Central  Google Scholar 

  176. Wang Y, Zhao R, Wang B, et al. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74:1–13.

    Article  PubMed  Google Scholar 

  177. Pai CG, Thomas CP, Biswas A, Rao S, Ramnarayan K. Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer: comparison with triple therapy. Indian J Gastroenterol. 2003;22:85–7.

  178. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88:33–45.

  179. Song Z, Suo B, Zhang L, Zhou L. Rabeprazole, minocycline, amoxicillin, and bismuth as first-line and second-line regimens for Helicobacter pylori eradication. Helicobacter. 2016;21:462–70.

    Article  CAS  PubMed  Google Scholar 

  180. Gisbert JP. H. pylori Study Group of the Spanish Gastroenterology Association. Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:1484–5.

    Article  CAS  PubMed  Google Scholar 

  181. Jeong MH, Chung J-W, Lee SJ, et al. Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori. Korean J Gastroenterol. 2012;59:401–6.

    Article  PubMed  Google Scholar 

  182. Yun S-P, Seon HG, Ok CS, et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6:452–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  183. Noh HM, Hong SJ, Han JP, et al. Eradication rate by duration of third-line rescue therapy with levofloxacin after Helicobacter pylori treatment failure in clinical practice. Korean J Gastroenterol. 2016;68:260–4.

    Article  PubMed  Google Scholar 

  184. Wang B, Wang Y-H, Lv Z-F, et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20:79–88.

    Article  CAS  PubMed  Google Scholar 

  185. Song ZQ, Liu J, Zhou LY. Hybrid therapy regimen for Helicobacter pylori eradication. Chin Med J (Engl). 2016;129:992–9.

    Article  CAS  Google Scholar 

  186. Tsay F-W, Wu D-C, Yu H-C, et al. A randomized controlled trial shows that both 14-day hybrid and bismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with moderate antibiotic resistance. Antimicrob Agents Chemother. 2017;61:e00140–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Battaglia G, Di Mario F, Vigneri S, et al. Strategy for the retreatment of failed Helicobacter pylori eradication therapy: a case series. Ital J Gastroenterol Hepatol. 1998;30:370–4.

    CAS  PubMed  Google Scholar 

  188. Nagahara A, Miwa H, Ohkura R, et al. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2001;16:613–8.

    Article  CAS  PubMed  Google Scholar 

  189. Perri F, Villani MR, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-based triple therapies after failure of the standard Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment Pharmacol Ther. 2001;15:1017–22.

  190. Tan B, Yang J-C, Young CL, et al. Helicobacter pylori antimicrobial susceptibility testing-guided salvage therapy in the USA: a real life experience. Dig Dis Sci. 2018;63:437–45.

    Article  CAS  PubMed  Google Scholar 

  191. Costa S, Soares J-B, Gonçalves R. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2017;29:1258–63.

    Article  PubMed  Google Scholar 

  192. Puig I, López-Góngora S, Calvet X, et al. Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection. Ther Adv Gastroenterol. 2016;9:437–48.

    Article  CAS  Google Scholar 

  193. Ahuja V, Bhatia V, Dattagupta S, Raizada A, Sharma MP. Efficacy and tolerability of rifampicin-based rescue therapy for Helicobacter pylori eradication failure in peptic ulcer disease. Dig Dis Sci. 2005;50:630–3.

  194. Mori H, Suzuki H, Matsuzaki J, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. United European Gastroenterol J. 2016;4:380–7.

    Article  CAS  PubMed  Google Scholar 

  195. Liu X, Wang H, Lv Z, et al. Rescue Therapy with a proton pump inhibitor plus amoxicillin and rifabutin for Helicobacter pylori infection: a systematic review and meta-analysis. Gastroenterol Res Pract. 2015;2015:415648.

    Article  PubMed  PubMed Central  Google Scholar 

  196. Zhuge L, Wang Y, Wu S, Zhao RL, Li Z, Xie Y. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis. Helicobacter. 2018;23:e12468.

  197. Zullo A, Ierardi E, Hassan C, Francesco VD. Furazolidone-based therapies for Helicobacter pylori Infection: A pooled-data analysis. Saudi J Gastroenterol. 2012;18:11–7.

    Article  PubMed  PubMed Central  Google Scholar 

  198. Francesco VD, Ierardi E, Hassan C, Zullo A. Furazolidone therapy for Helicobacter pylori: is it effective and safe? World J Gastroenterol. 2009;15:1914–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  199. Kobierska-Szeliga M, Czeczot H. Characterization of the genotoxic properties of nitrofurans: nitrofurazone and furazolidone. Acta Biochim Pol. 1994;41:1–5.

    Article  CAS  PubMed  Google Scholar 

  200. Gisbert JP, Barrio J, Modolell I, et al. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci. 2015;60:458–64.

    Article  CAS  PubMed  Google Scholar 

  201. Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter. 2018;23:e12485.

  202. Furuta T, Sugimoto M, Yamade M, et al. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. Intern Med. 2014;53:571–5.

    Article  PubMed  Google Scholar 

  203. Niv Y. Doxycycline in eradication therapy of Helicobacter pylori--a systematic review and meta-analysis. Digestion. 2016;93:167–73.

    Article  CAS  PubMed  Google Scholar 

  204. Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017;22. https://doi.org/10.1111/hel.12374.

  205. Hu Y, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46:773–9.

    Article  CAS  PubMed  Google Scholar 

  206. Niv Y, Hazazi R. Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter. 2008;13:56–61.

    Article  PubMed  Google Scholar 

  207. Bapat MR, Abraham P, Bhandarkar PV, Phadke AY, Joshi AS. Acquisition of Helicobacter pylori infection and reinfection after its eradication are uncommon in Indian adults. Indian J Gastroenterol. 2000;19:172–4.

  208. Rekha T, Khan AA, Alavi A, et al. Genetic fine structure analysis of Helicobacter pylori isolates before and after treatment. Indian J Med Microbiol. 2003;21:166–71.

    Article  CAS  PubMed  Google Scholar 

  209. Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med. 1999;106:222–6.

    Article  CAS  PubMed  Google Scholar 

  210. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7.

    Article  PubMed  Google Scholar 

  211. Ma J-L, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  212. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.

    Article  CAS  PubMed  Google Scholar 

  213. Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H. pylori infection with gastric carcinoma: a Meta analysis. World J Gastroenterol. 2001;7:801–4.

  214. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999;94:2373–9.

  215. Singh K, Ghoshal UC. Causal role of Helicobacter pylori infection in gastric cancer: An Asian enigma. World J Gastroenterol. 2006;12:1346–51.

    Article  PubMed  PubMed Central  Google Scholar 

  216. Ghoshal UC, Chaturvedi R, Correa P. The enigma of Helicobacter pylori infection and gastric cancer. Indian J Gastroenterol. 2010;29:95–100.

    Article  PubMed  PubMed Central  Google Scholar 

  217. Ghoshal UC, Kumar S, Krishnani N, Kumari N, Chourasia D, Tripathi S. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection. Trop Gastroenterol. 2011;32:292–8.

  218. Kate V, Ananthakrishnan N. Helicobacter pylori and gastric carcinoma: evidence for the link. Natl Med J India. 2000;13:329.

    CAS  PubMed  Google Scholar 

  219. Ghoshal UC, Tiwari S, Dhingra S, et al. Frequency of Helicobacter pylori and CagA antibody in patients with gastric neoplasms and controls: the Indian enigma. Dig Dis Sci. 2008;53:1215–22.

    Article  PubMed  Google Scholar 

  220. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--first American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735–40.

    CAS  PubMed  Google Scholar 

  221. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12 Suppl 2:32–8.

  222. Kong Y-J, Yi H-G, Dai J-C, Wei M-X. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol. 2014;20:5903–11.

    Article  PubMed  PubMed Central  Google Scholar 

  223. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  224. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011;83:253–60.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The members of the ISG Task Force on Helicobacter pylori thank Kalinga Gastroenterology Foundation, Cuttack, India, for providing an unrestricted grant to conduct the Consensus workshops on Management of Helicobacter pylori infection in Indians.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Srirama Chandra Bhanja Medical College and Hospital, Cuttack, 753 007, India

    Shivaram Prasad Singh

  2. Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, 110 029, India

    Vineet Ahuja & Govind Makharia

  3. Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow, 226 014, India

    Uday C. Ghoshal

  4. Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160 012, India

    Usha Dutta & Saroj K. Sinha

  5. Department of Gastroenterology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, 190 011, India

    Showkat Ali Zargar

  6. Department of Hepatology, Sri Ramachandra Medical Centre, No. 1 Ramachandra Nagar, Porur, Chennai, 600 116, India

    Jayanthi Venkataraman

  7. Department of Gastrointestinal Sciences, Christian Medical College and Hospital, Vellore, 632 004, India

    Amit Kumar Dutta

  8. Division of Bacteriology, National Institute of Cholera and Enteric Diseases, Kolkata, 700 010, India

    Asish K Mukhopadhyay

  9. Department of Gastroenterology, IMS and Sum Hospital, Bhubaneswar, 756 001, India

    Ayaskanta Singh & Manoj K. Sahu

  10. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Superspeciality of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160 012, India

    Babu Ram Thapa

  11. Department of Histopathology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160 012, India

    Kim Vaiphei

  12. Department of Pediatric Gastroenterology, Kanchi Kamakoti Childs Trust Hospital, Chennai, 600 034, India

    Malathi Sathiyasekaran

  13. Department of Pathology, Acharya Harihar Post Graduate Institute of Cancer, Manglabag, Cuttack, 753 007, India

    Niranjan Rout

  14. P D Hinduja Hospital and Medical Research Centre, Veer Savarkar Marg, Cadel Road, Mahim, Mumbai, 400 016, India

    Philip Abraham

  15. Gastro and Kidney Care Hospital, IRC Village, Nayapalli, Bhubaneswar, 751 015, India

    Prakash Chandra Dalai

  16. Department of Gastroenterology, Topiwala National Medical College and B Y L Nair Charitable Hospital, Dr Anandrao Laxman Nair Marg, Mumbai, 400 008, India

    Pravin Rathi

  17. Department of Gastroenterology and Hepatobiliary Sciences, Sir HN Reliance Foundation Hospital and Research Centre, Raja Rammohan Roy Road, Prarthana Samaj, Girgaon, Mumbai, 400 004, India

    Shobna Bhatia

  18. Department of Pathology, All India Institute of Medical Sciences, Patrapada, Bhubaneswar, 751 019, India

    Susama Patra

  19. Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow, 226 014, India

    Ujjala Ghoshal

  20. Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 226 014, India

    Ujjal Poddar

  21. Anjani Superspeciality Hospital, Amaravathi, Guntur, 522 001, India

    Venigalla Pratap Mouli

  22. Department of Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, 605 006, India

    Vikram Kate

Authors
  1. Shivaram Prasad Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vineet Ahuja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uday C. Ghoshal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Govind Makharia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Usha Dutta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Showkat Ali Zargar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jayanthi Venkataraman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Amit Kumar Dutta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Asish K Mukhopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ayaskanta Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Babu Ram Thapa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kim Vaiphei
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Malathi Sathiyasekaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Manoj K. Sahu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Niranjan Rout
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Philip Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Prakash Chandra Dalai
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Pravin Rathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Saroj K. Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Shobna Bhatia
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Susama Patra
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Ujjala Ghoshal
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Ujjal Poddar
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Venigalla Pratap Mouli
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Vikram Kate
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S. P. S., V. A., U. C. G., G. M., U. D., S. A. Z., and J. V. generated the initial list of statements. S. P. S., G. M., and V. A. constituted the core committee and coordinated with the participants for the consensus meeting/voting. A. K. D., A. K. M., A. S., B. R. T., K. P., M. S., M. K. S., N. R., P. A., P. C. D., P. R., S. K. S., S. B., S. P., U. G., U. P., V. P. M., and V. K. presented the statements with the evidence in the consensus meeting. All of these members and other delegate members of the ISG Task Force voted in the consensus meeting. All authors approved the manuscript.

Corresponding author

Correspondence to Shivaram Prasad Singh.

Ethics declarations

Conflict of interest

VA, UCG, GM, UD, SAZ, JV, AKD, AKM, AS, BRT, KV, MS, MKS, NR, PA, PCD, PR, SKS, SB, SP, UG, UP, VPM, and VK declare that they have no conflict of interest in relation to this paper.SPS owns stock for Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories, and Panacea Biotec.

Ethical statement

The study was performed in a manner to conform with the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.

Disclaimer

The authors are solely responsible for the data and the contents of the paper. In no way are the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or the printer/publishers responsible for the results/findings and content of this article.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Shivaram Prasad Singh and Vineet Ahuja are first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, S.P., Ahuja, V., Ghoshal, U.C. et al. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian J Gastroenterol 40, 420–444 (2021). https://doi.org/10.1007/s12664-021-01186-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-021-01186-4

Keywords

Search

Navigation